Jian-Wei Zhu

Discovery and Optimization of the Novel Immunotoxins Targeting TROP2 for Cancer Therapy

The therapeutic potential of these novel anti-TROP2 immunotoxins against TROP2-overexpressing tumors is demonstrated and five doses of either dsT3PE or dsT3PE_ABD_CC at 3 mg/kg could significantly reduce tumor progression in the NCI-N87 mouse xenograft model.

A CXCR4/PD-L1 Bispecific Nanobody Engineered for Tumor Microenvironment Retention Mediates Sustained Synergy with Chemotherapy via Remodeling Immunity in TNBC

These findings reveal that dual blockade of PD-L1 and CXCR4 acts synergistically with chemotherapy by triggering tumor cell apoptotic effects and reversing the immunosuppressive microenvironment, thereby emerging as a promising therapeutic strategy for TNBC.

[Experimental and computational analyses of altered cetuximab binding induced by EGFR mutations].